Unharmonious ivonescimab reveal for Summit
The same trial that sent Summit up 272% sees the stock crash 36%.
AUA 2025 – Pfizer catches the Crest of a subQ wave
But sasanlimab's use looks set to remain narrow.
AUA 2025 – J&J scores in a new bladder cancer use
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
Genor goes one better
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
ASCO 2025 preview – late-breakers in focus
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
